Tirzepatide 5mg plateau claims: what the data actually shows

What did @tirzewithkia actually say?

Not a whole lot, technically. The transcript is mostly reaction commentary: "there's a few more blemishes on the card" and "just look at that." The video's substance lives in the caption, not the spoken words. She reports being on tirzepatide 5mg, seeing minimal change, and frames it with "it's NOT a gain" as a small consolation. That framing is worth examining.

This is a progress check, not a medical claim. She is not prescribing anything, not promising outcomes, and not diagnosing. The content is personal documentation. That context matters for how we evaluate it.

Does the science back this up?

Yes, actually. Slower response at 5mg is documented and expected for many patients. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed that tirzepatide's most significant weight loss effects were dose-dependent, with 10mg and 15mg producing substantially greater reductions than lower doses. Patients at 5mg still lost meaningful weight on average, but the effect was smaller and slower.

What the data also shows is that titration schedules exist for a reason. Patients typically start at 2.5mg and step up every four weeks precisely because the therapeutic window opens wider at higher doses while the body adjusts. "Not much change" at 5mg is not a red flag. It is a common waypoint.

• SURMOUNT-1 found 15mg tirzepatide produced ~20.9% body weight reduction vs. ~15% at 5mg over 72 weeks.
• Response variance is real: some patients are early responders, others plateau until dose escalation.
• Appetite suppression and metabolic effects can lag behind the dose increase by several weeks.

What did they get wrong (or right)?

She got the framing right. Reframing a slow week as "not a gain" is accurate and arguably the healthiest way to interpret early-phase GLP-1 therapy. Weight loss with tirzepatide is not linear. Expecting dramatic results at 5mg is a common source of early dropout, and her measured expectations align with what the clinical data actually shows for this dose range.

There is nothing clinically incorrect in what she said. If anything, the risk in videos like this is what is implied but unsaid: viewers may compare their own 5mg results to hers and draw conclusions that do not apply to them. Individual response to tirzepatide varies based on baseline weight, metabolic rate, dietary changes, and genetic factors. One person's "not much change" is another person's significant loss.

The bigger concern is not this video. It is the broader GLP-1 TikTok ecosystem where people self-adjust doses based on peer progress comparisons. That is a genuine harm pattern, and this video does not contribute to it.

What should you actually know?

If you are on tirzepatide 5mg and feeling impatient, the clinical evidence suggests patience is the right call. The SURMOUNT-2 trial (Garvey et al., 2023, The Lancet) confirmed that therapeutic benefit continues to accumulate through the titration period and beyond. Early non-response does not predict final outcome.

A few things that are actually worth knowing:

• "Not much change" is not the same as treatment failure. Tirzepatide has a titration curve, and 5mg is not the ceiling for most people.
• Dose escalation decisions should come from your prescriber, not from comparing your progress card to someone else's TikTok.
• Side effect profiles often shift between doses, so slower escalation can reduce GI distress.
• Weight is one metric. Blood sugar regulation, appetite changes, and energy can shift before the scale moves significantly.
• Compounded tirzepatide and brand-name Zepbound or Mounjaro are not interchangeable products. If you are using a compounded version, the formulation may differ.

The video is benign. The impulse to chase faster results by pushing doses without medical guidance is where the real risk lives.